NP546999.RAgciLvXxCuf-XXdCJCxxby54-ifiXqzGOkYqzYbPgkkA
type: Nanopublication
has assertion: NP546999.RAgciLvXxCuf-XXdCJCxxby54-ifiXqzGOkYqzYbPgkkA130 assertion
has provenance: NP546999.RAgciLvXxCuf-XXdCJCxxby54-ifiXqzGOkYqzYbPgkkA130 provenance
has publication info: NP546999.RAgciLvXxCuf-XXdCJCxxby54-ifiXqzGOkYqzYbPgkkA130 publicationInfo
created: 2014-10-02T12:37:30+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetrdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v2.1.0.0

NP546999.RAgciLvXxCuf-XXdCJCxxby54-ifiXqzGOkYqzYbPgkkA130 assertion
type: Assertion
description: [The importance of Sp1 binding suggests that therapy targeting the AR-Sp1 complex may dampen VEGF induced angiogenesis and, thereby, block prostate cancer progression, helping to maintain the indolent form of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/23369005
was generated by: ECO_0000203

befree-20140225
imported on: 2014-02-25

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetrdf
version: v2.1.0